Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge
about
ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapiesAnthrax prophylaxis: recent advances and future directionsImproving the predictive value of interventional animal models dataHumoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in HumansEvaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's diseaseCharacterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity.Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.Progress, challenges, and opportunities in Francisella vaccine development.Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen.Extrapolating from animals to humans.Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis.Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
P2860
Q24289195-042FABC4-0F4F-4A3D-8738-76C04D9D7BB3Q26781366-787BDAA0-D86D-432B-BA58-8B490823E475Q27026822-D7AC2978-3A8A-4E71-9DD3-CACE8F7A9BE7Q28391301-D8EFD4FE-8393-4499-B9D8-B3EEF91D7007Q30152051-9C16AE33-01DC-44E8-83A9-8A221725B193Q35341887-4725B59B-D6A7-4ADB-8752-7A004412D128Q35853440-B3333239-637B-43DB-B0CA-50EE1CC25ED8Q35900460-6E827EA3-8742-42B9-BCD5-DC9DAB260E20Q35935173-1BA7806E-BF6B-49AD-9097-96B9143F514FQ36275707-E256F60A-FEBD-4D81-95C0-0C086790066CQ36970210-919CCA2C-596E-44C7-B9C2-11859C69EBE5Q36970295-6AE25EBB-DFD6-4357-8939-BB28DE53E1A4Q37530303-803132A7-3550-47EE-A8CC-68AF8CC01F3AQ37545021-378D0A29-FE75-4AE9-8922-8C5248157528Q39456004-4A94C70E-A037-456E-A46D-556AF46EA4D0Q39892106-9931FDCD-9BBB-46F8-BA7F-D3023544ADBFQ39948347-61032221-2FC6-4A9A-89AC-4AE3FADD587CQ41755913-D49C64FC-5CA6-4B85-87FA-D6640A57FC36Q41966010-99522BB6-A875-4FD3-AB74-B281ED955D57Q46826177-CADB9C4D-3B96-47CD-807F-41095D782AA3Q46936728-97BD8AB0-D3A3-4CAB-AA45-AAFB74596A96Q47162390-CD3BE68F-B0DB-4749-9A74-1DC0AE7E66EDQ49444286-D954A7D4-3CA5-4505-B0D8-5EC23106027AQ55361721-0C27536A-5AC4-46A1-8134-EF022530EF57
P2860
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@ast
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@en
type
label
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@ast
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@en
prefLabel
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@ast
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@en
P2093
P2860
P1476
Anthrax vaccine-induced antibo ...... survival to aerosol challenge
@en
P2093
Dean A Follmann
Edwin O Nuzum
Freyja Lynn
Gregory V Stark
Jarad M Schiffer
Robert Kohberger
P2860
P304
P356
10.1126/SCITRANSLMED.3004073
P407
P577
2012-09-01T00:00:00Z